Clinical use of hyaluronic acid in andrology: A review.
Peyronie's disease
hyaluronic acid
penile enlargement
premature ejaculation
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
28
06
2021
received:
03
05
2021
accepted:
19
07
2021
pubmed:
24
7
2021
medline:
3
3
2022
entrez:
23
7
2021
Statut:
ppublish
Résumé
Hyaluronic acid is a glycosaminoglycan widely used in the fields of orthopedics, ophthalmology, and aesthetic medicine due to its significant ability to reduce the synthesis of pro-inflammatory proteins and its activity against oxidative stress, a feature of many degenerative illnesses. The objective of the present review is to provide a comprehensive narrative review of the most recent literature on the use of hyaluronic acid in andrology in order to facilitate the use of this therapeutic device in the common clinical practice of many physicians. Specific conditions covered in the review are Peyronie's disease, premature ejaculation, and penile enlargement. A broad and comprehensive literature search included Medline, EMBASE, and the Cochrane Libraries, with no time restriction up to December 2020 and restricted to English language publications. Unpublished studies were not included. The study was registered as "The role of hyaluronic acid in andrology: A systematic review and meta-analysis" in PROSPERO with the ID CRD42021223416. Hyaluronic acid is a valid choice for the treatment of Peyronie's disease in terms of the resolution of the acute phase of the disease and of contributing to stabilizing the disease as a bridge to potential surgery. Data, furthermore, suggest that hyaluronic acid is frequently associated with an overall clinical improvement, allowing the patient to resume normal sexual activity. With regard to premature ejaculation, data suggests hyaluronic acid-based treatments were effective in prolonging intra-vaginal ejaculation time. Furthermore, hyaluronic acid was found to be safe and well-tolerated, with main adverse events limited to local discomfort, ecchymosis, papule formation, and glans numbness, all of which were reported to resolve spontaneously. Last, with regard to penile enlargement, the overall perception of experts is that hyaluronic acid may be an extremely well-tolerated compound with potential for application in specific areas of male sexual health that are often neglected as compared to more common, and relatively simpler to treat, conditions.
Sections du résumé
BACKGROUND
Hyaluronic acid is a glycosaminoglycan widely used in the fields of orthopedics, ophthalmology, and aesthetic medicine due to its significant ability to reduce the synthesis of pro-inflammatory proteins and its activity against oxidative stress, a feature of many degenerative illnesses.
OBJECTIVES
The objective of the present review is to provide a comprehensive narrative review of the most recent literature on the use of hyaluronic acid in andrology in order to facilitate the use of this therapeutic device in the common clinical practice of many physicians. Specific conditions covered in the review are Peyronie's disease, premature ejaculation, and penile enlargement.
MATERIALS AND METHODS
A broad and comprehensive literature search included Medline, EMBASE, and the Cochrane Libraries, with no time restriction up to December 2020 and restricted to English language publications. Unpublished studies were not included. The study was registered as "The role of hyaluronic acid in andrology: A systematic review and meta-analysis" in PROSPERO with the ID CRD42021223416.
DISCUSSION AND CONCLUSION
Hyaluronic acid is a valid choice for the treatment of Peyronie's disease in terms of the resolution of the acute phase of the disease and of contributing to stabilizing the disease as a bridge to potential surgery. Data, furthermore, suggest that hyaluronic acid is frequently associated with an overall clinical improvement, allowing the patient to resume normal sexual activity. With regard to premature ejaculation, data suggests hyaluronic acid-based treatments were effective in prolonging intra-vaginal ejaculation time. Furthermore, hyaluronic acid was found to be safe and well-tolerated, with main adverse events limited to local discomfort, ecchymosis, papule formation, and glans numbness, all of which were reported to resolve spontaneously. Last, with regard to penile enlargement, the overall perception of experts is that hyaluronic acid may be an extremely well-tolerated compound with potential for application in specific areas of male sexual health that are often neglected as compared to more common, and relatively simpler to treat, conditions.
Identifiants
pubmed: 34297894
doi: 10.1111/andr.13083
pmc: PMC9135118
doi:
Substances chimiques
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-50Informations de copyright
© 2021 American Society of Andrology and European Academy of Andrology.
Références
Nat Rev Urol. 2015 Nov;12(11):629-40
pubmed: 26502991
Int J Impot Res. 2003 Dec;15(6):439-43
pubmed: 14671664
J Sex Med. 2019 Apr;16(4):577-585
pubmed: 30833149
J Rheumatol. 2000 Jul;27(7):1713-20
pubmed: 10914857
J Urol. 1997 Dec;158(6):2284-90
pubmed: 9366377
J Urol. 1994 Jul;152(1):105-6
pubmed: 8201639
Int Braz J Urol. 2008 Jul-Aug;34(4):457-66; discussion 466
pubmed: 18778497
J Sex Med. 2009 Oct;6(10):2888-95
pubmed: 19627471
J Urol. 1997 Jan;157(1):306-10
pubmed: 8976286
Dermatol Surg. 2012 Feb;38(2):e1-7
pubmed: 22171624
Int J Impot Res. 2002 Oct;14(5):361-74
pubmed: 12454687
Inflamm Res. 1999 Jul;48(7):399-403
pubmed: 10450790
Int J Impot Res. 2004 Dec;16(6):547-51
pubmed: 15057258
J Urol. 1996 May;155(5):1617-20
pubmed: 8627836
J Clin Med. 2020 Apr 05;9(4):
pubmed: 32260508
Adv Dermatol. 2007;23:1-31
pubmed: 18159893
J Sex Med. 2011 Dec;8(12):3407-13
pubmed: 20233296
Asian J Androl. 2008 Jan;10(1):79-87
pubmed: 18087647
Sex Med. 2016 Jun;4(2):e83-8
pubmed: 26984291
J Sex Med. 2013 Jan;10(1):294-303
pubmed: 22512935
Joint Bone Spine. 2007 Jul;74(4):324-9
pubmed: 17590367
Biol Reprod. 2005 Dec;73(6):1199-210
pubmed: 16093362
Andrology. 2017 Jul;5(4):771-775
pubmed: 28718527
Int J Impot Res. 2013 May;25(3):117-20
pubmed: 23552577
Int J Impot Res. 2019 Sep;31(5):348-355
pubmed: 30610210
J Sex Med. 2020 Jan;17(1):133-141
pubmed: 31735613
Int Urol Nephrol. 2015 Oct;47(10):1595-602
pubmed: 26257044
J Urol. 1990 Dec;144(6):1376-9
pubmed: 2231932
J Urol. 1997 Jan;157(1):298-302
pubmed: 8976284
Sex Med. 2014 Jun;2(2):41-59
pubmed: 25356301
Int J Impot Res. 2002 Oct;14(5):345-52
pubmed: 12454685
J Sex Med. 2016 Feb;13(2):144-52
pubmed: 26953829
Plast Reconstr Surg. 2020 Nov;146(5):995-1006
pubmed: 33136942
World J Mens Health. 2021 Jul;39(3):526-532
pubmed: 33151042
Eur Urol. 2016 May;69(5):904-16
pubmed: 26749092
Aesthet Surg J. 2013 Feb;33(2):258-64
pubmed: 23388646
Int J Impot Res. 2008 Jul-Aug;20(4):425-8
pubmed: 18548080
J Urol. 2003 Apr;169(4):1234-41
pubmed: 12629334
J Urol. 1997 Oct;158(4):1388-90
pubmed: 9302127
World J Mens Health. 2021 Apr;39(2):352-357
pubmed: 32009312
J Urol. 1997 Jan;157(1):311-5
pubmed: 8976287
Exp Gerontol. 2014 Apr;52:30-5
pubmed: 24487346
Mol Cell Proteomics. 2009 Jan;8(1):172-89
pubmed: 18784066
Osteoarthritis Cartilage. 2003 Oct;11(10):747-55
pubmed: 13129694
J Proteomics. 2014 Mar 17;99:40-53
pubmed: 24480285
Int J Impot Res. 2019 Jul;31(4):245-255
pubmed: 30478264
Andrology. 2022 Jan;10(1):42-50
pubmed: 34297894
Osteoarthritis Cartilage. 2005 Aug;13(8):643-54
pubmed: 15936958
Andrologia. 2012 May;44 Suppl 1:650-3
pubmed: 22013959
World J Mens Health. 2015 Aug;33(2):50-61
pubmed: 26331121
J Sex Med. 2009 Oct;6(10):2868-77
pubmed: 19656274